

INFORMATION DISCLOSURE STATEMENT

Applicant	: Carrara et al.
App. No	: Unknown
Filed	: Herewith
For	: TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES
Examiner	: Unknown
Art Unit	: Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 7 references to be considered by the Examiner. Also enclosed are 6 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 7, 2006

By: 
Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	AP9 Rec'd PCT/PTO 07 APR 2006
	Filing Date	Herewith
	First Named Inventor	Carrara, Dario Norberto R.
	Art Unit	Unknown
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 1 OF 1	Attorney Docket No.	KLAUS6.001APC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,580,574	12-03-1996	Behl et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	2	EP 1 325 752 A2	07-09-2003	Antares Pharma IPL AG		
	3	WO 95/29678	11-09-1995	F. Hoffmann-La Roche AG		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	4	LIPP, R. (1998) "Selection and use of crystallization inhibitors for matrix-type transdermal drug-delivery systems containing sex steroids" J. Pharm. Pharmacol. 50:1343-1349.	
	5	KOTIYAN, P.N. et al. (2001) "Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol" European Journal of Pharmaceutics and Biopharmaceutics 52:173-180.	
	6	MOSER, K. et al. (2001) "Passive skin penetration enhancement and its quantification in vitro" European Journal of Pharmaceutics and Biopharmaceutics 52:103-112.	
	7	MURA, P. et al. (2000) "Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations" European Journal of Pharmaceutical Sciences 9:365-372.	

2503392
040506

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.